Business Monitor International


Czech Republic Pharmaceuticals & Healthcare Report

Published 10 April 2014

  • 101 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Czech Republic Pharmaceuticals & Healthcare Report

BMI View: Overall, t he Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services is expected to continue its steady growth trajectory, putting pressure on the state and insurers to raise premiums or redistribute funding. Following the release of pharmaceutical sales data by the SUKL, we have significantly revised down historical values for 2013 and forecasts from 2014 onwards. We had originally envisaged a bounce in sales in H213 that would see the market growth flatten in 2013, but a slackening in demand from the hospital sector saw the pharmaceutical market decline in 2013. The newly-elected, centre-left coalition government has outlined a policy of further cost-containment, and this has weighed heavily on the future growth prospects of the market. Despite these medium-term concerns, BMI maintains a more optimistic long-term view. We believe that the need for innovative medicines will drive growth well above the rates of expansion achieved in Western Europe over our 10-year forecast period.

Headline Expenditure Projections

  • Pharmaceuticals: CZK76.93bn (US$3.66bn) in 2013 to CZK78.07bn (US$3.58bn) in 2014; 1.5% in local currency terms and -2.1% in US dollar terms. Lower compared to previous quarter.

  • Healthcare: CZK282.48bn (US$13.43bn) in 2013 to CZK300.90bn (US$13.80bn) in 2014; +6.5% in local currency terms and 2.8% in US dollar terms. Historical revision to 2012 figure.

Risk/Reward Rating: Despite leading our regional RRR table with a score of 62.0 out of 100 and therefore ranked as the most attractive market in the Central and Eastern European region followed by Poland (61.5) and Russia (59.2) in Q214, drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure, poor access to the market and increasing generic substitution. Additionally, adopted and proposed amendments to...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Czech Republic Pharmaceutical Sales, Historical Data And Forecasts
15
Healthcare Market Forecast
16
Table: Czech Republic Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Czech Republic Government Healthcare Expenditure Trends, Historical Data And Forecasts
18
Table: Czech Republic Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market Forecast
19
Table: Czech Republic Prescription Drug Market Indicators, Historical Data And Forecasts
20
Patented Drug Market Forecast
21
Table: Czech Patented Drug Market Indicators, Historical Data And Forecasts
22
Generic Drug Market Forecast
23
Table: Czech Republic Generic Drug Market Indicators, Historical Data And Forecasts
23
OTC Medicine Market Forecast
24
Table: Czech Republic Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
26
Pharmaceutical Trade Forecast
27
Table: Czech Republic Pharmaceutical Trade Data And Forecasts (US$mn)
28
Table: Czech Republic Pharmaceutical Trade Data And Forecasts (CZKmn)
28
Other Healthcare Data
28
Key Risks To BMI's Forecast Scenario
29
Macroeconomic Forecasts
30
Economic Analysis
30
Table: Czech Republic - Economic Activity
35
Industry Risk Reward Ratings
36
Central And Eastern Europe Risk
Central And Eastern Europe Risk
Czech Republic Risk
Czech Republic Risk
Rewards
42
Risks
42
Market Overview
43
Industry Trends And Developments
44
Epidemiology
44
Healthcare Sector
45
Healthcare Insurance
46
Healthcare Reforms
46
Hospital Sector
48
Research & Development
49
Clinical Trials
50
Regulatory Development
52
Regulatory Regime
52
Intellectual Property Environment
52
Prescribing Rules
53
Pharmaceutical Advertising
53
Pricing Regime
54
Reimbursement Regime
55
Recent Pricing And Reimbursement Developments
56
Changes To VAT
59
Table: European VAT Rates On Medicines (%)
59
Electronic Tenders
60
Competitive Landscape
62
Pharmaceutical Sector
62
Foreign Industry
63
Company Developments
63
Pharmaceutical Wholesale
63
Pharmaceutical Retail Sector
64
Table: Retail Pharmacy Market Overview, 2004-2010
64
Company Profile
68
Zentiva (Sanofi)
68
Walmark
72
AstraZeneca
76
Bristol-Myers Squibb
78
Sanofi
80
Novartis
83
GlaxoSmithKline
85
Pfizer
88
Demographic Forecast
90
Demographic Outlook
90
Table: The Czech Republic's Population By Age Group, 1990-2020 ('000)
91
Table: The Czech Republic's Population By Age Group, 1990-2020 (% of total)
92
Table: The Czech Republic's Key Population Ratios, 1990-2020
93
Table: The Czech Republic's Rural And Urban Population, 1990-2020
93
Glossary
94
Methodology
96
Pharmaceutical Expenditure Forecast Model
96
Healthcare Expenditure Forecast Model
96
Notes On Methodology
97
Risk
Risk
Ratings Overview
99
Table: Pharmaceutical Risk
Table: Pharmaceutical Risk
Indicator Weightings
100

The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Czech Republic to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc